8-K: Niki BioSolutions and DiamiR Biosciences Complete Merger

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) and DiamiR Biosciences Corp. have completed their merger, establishing a new entity focused on biopharmaceutical and diagnostics.

Summary

• Niki BioSolutions, Inc. (formerly Aptorum Group Limited) and DiamiR Biosciences Corp. have completed their merger, effective July 20, 2026.
• The transaction involved Aptorum Group redomiciling from the Cayman Islands to Delaware and changing its name to Niki BioSolutions, Inc.
• DiamiR Biosciences Corp. has become a wholly-owned subsidiary of Niki BioSolutions, Inc.
• The combined company's common stock will trade on the Nasdaq Capital Market under the symbol 'NIKI'.
• A 1-for-10 reverse stock split was implemented for Aptorum Group's shares prior to the merger's completion.
• A new Stockholders Agreement was entered into by Niki BioSolutions and its stockholders.
• The company has adopted the 2026 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, marking the successful completion of a significant strategic transaction that positions the combined entity for future growth in the biopharmaceutical and diagnostics markets.

Positives

• Completion of the merger between Aptorum Group and DiamiR Biosciences, creating a combined entity with a focus on biopharmaceuticals and diagnostics.
• Successful redomiciliation of Aptorum Group to Delaware and name change to Niki BioSolutions, Inc.
• Listing on the Nasdaq Capital Market under the ticker 'NIKI', providing enhanced visibility and access to capital markets.
• Implementation of a 1-for-10 reverse stock split to meet Nasdaq's minimum bid price requirement.
• Adoption of the 2026 Equity Incentive Plan to attract and retain talent.

Negatives

• The reverse stock split, while necessary for Nasdaq compliance, can sometimes be perceived negatively by investors.
• The complexity of the merger and associated corporate actions may lead to temporary confusion among stakeholders.

Risks

• The filing does not explicitly detail specific risks associated with the merger's integration or future operations, beyond standard forward-looking statement disclaimers.
• Potential challenges in integrating the operations and cultures of Aptorum Group and DiamiR Biosciences.
• The success of Niki BioSolutions will depend on its ability to navigate the competitive biopharmaceutical and diagnostics markets.

Future Outlook

The company is positioned to leverage the combined expertise and technologies of Aptorum Group and DiamiR Biosciences in the biopharmaceutical and diagnostics sectors. The adoption of the 2026 Equity Incentive Plan aims to align employee incentives with long-term company growth.

Management Comments

• The merger is expected to close on or about July 20, 2026.
• The reverse stock split is intended to increase the per share trading price of the post-Merger Company's common stock to enable the post-Merger Company to maintain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• The combined company will be renamed Niki BioSolutions, Inc., a Delaware company.

Industry Context

StockSavvy.ai notes that the completion of this merger signifies a strategic consolidation within the biopharmaceutical and diagnostics sectors, aiming to create a more robust entity capable of advancing therapeutic and diagnostic solutions. The redomestication to Delaware and Nasdaq listing are common strategies for growth-oriented companies seeking to enhance their corporate profile and access to capital.

Management Changes

Corporate Governance

Related Party Transactions

• The Stockholders Agreement outlines specific rights and obligations for Primary Stockholder Parties, including designation rights for board seats and committee memberships, contingent on ownership thresholds.
• The agreement details voting requirements for Stockholder Reserved Matters, requiring Requisite Consent from Primary Stockholder Parties under certain ownership conditions.

Stakeholder Impact

• Shareholders of Aptorum Group and DiamiR Biosciences are now shareholders of Niki BioSolutions, Inc., with their holdings adjusted due to the reverse stock split and merger exchange ratios.
• Employees and management of both former companies are now part of Niki BioSolutions, Inc., with potential impacts from the 2026 Equity Incentive Plan.
• The Nasdaq listing provides increased liquidity and potential for broader investor participation.

Next Steps

• Integration of DiamiR Biosciences into Niki BioSolutions, Inc.
• Ongoing operations and development of therapeutic and diagnostic assets.
• Compliance with Nasdaq listing requirements.
• Potential future capital raises to fund operations and growth.

Key Dates

Recommendation

The completion of the merger and Nasdaq listing are significant positive steps. However, the success of the combined entity hinges on effective integration and execution in a competitive market. Further analysis of the company's pipeline, financial performance post-merger, and market reception is required before a stronger recommendation can be made. Therefore, a 'hold' is appropriate pending further developments.

Keywords

Niki BioSolutions, DiamiR Biosciences, Merger, Aptorum Group, Nasdaq, Biopharmaceutical, Diagnostics, Stockholders Agreement